NCT05034809 is a Phase 2 clinical trial of Melatonin 20 MG in Dengue Fever With Warning Signs, sponsored by Ilocos Training and Regional Medical Center.

Who is sponsoring NCT05034809?

NCT05034809 is sponsored by Ilocos Training and Regional Medical Center.

What drugs are being tested in NCT05034809?

Interventions in NCT05034809: Melatonin 20 MG.

What condition does NCT05034809 study?

NCT05034809 studies Dengue Fever With Warning Signs.

Is NCT05034809 still recruiting?

NCT05034809 is currently status unknown. Last updated 13 October 2021.

Last reviewed 2021-10-13 · How we verify

NCT05034809

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness Of High Dose Melatonin As Adjunctive Therapy For Dengue Fever With Warning Signs

Status unknown Phase 2 Last updated 13 October 2021

What this trial tests

Phase 2 trial testing Melatonin 20 MG in Dengue Fever With Warning Signs in 140 participants. Status unknown.

Timeline

20 October 2021

Primary endpoint
30 August 2022

30 October 2022

Quick facts

Lead sponsor	Ilocos Training and Regional Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	140
Start date	20 October 2021
Primary completion	30 August 2022
Estimated completion	30 October 2022

Drugs / interventions tested

Melatonin 20 MG — full drug profile →

Conditions studied

Dengue Fever With Warning Signs — all drugs for Dengue Fever With Warning Signs →

Sponsor

Ilocos Training and Regional Medical Center

Who can join

Adults 5 to 18, any sex, with Dengue Fever With Warning Signs. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dengue Hemorrhagic Fever is a mosquito-borne viral disease endemic in the Philippines which caused multiple epidemics. Most points to the activation of the complement system secondary to humoral respond leading to cytokine release causing systemic inflammation. Melatonin, is a hormone which has an a) anti-viral, b) immunomodulator, c) antioxidant, d) modulatory effect on hematopoiesis and e) anti-inflammatory action. This is a randomized control trial to determine the effectiveness of adjunctive melatonin therapy among patients diagnosed with Dengue fever with Warning Signs. This would include children aged 5 to 18 years old with no signs of hemmorhagic shock. They would be randomly assigned into 2 groups. Baseline Complete blood count with platelet (CBCPC) will be collected. Daily CBCPC will be collected and would be statistically analyze after the study.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular Mechanisms of Antiviral Agents against Dengue Virus.
Lee MF, Wu YS, Poh CL. · · 2023 · cited 66× · PMID 36992414 · DOI 10.3390/v15030705
Inhibitory Potential of Chromene Derivatives on Structural and Non-Structural Proteins of Dengue Virus.
Dharmapalan BT, Biswas R, Sankaran S, Venkidasamy B, et al · · 2022 · cited 7× · PMID 36560664 · DOI 10.3390/v14122656
Orthoflaviviral Inhibitors in Clinical Trials, Preclinical In Vivo Efficacy Targeting NS2B-NS3 and Cellular Antiviral Activity via Competitive Protease Inhibition.
Cavina L, Bouma MJ, Gironés D, Feiters MC. · · 2024 · cited 5× · PMID 39274895 · DOI 10.3390/molecules29174047
A systematic mapping review of therapeutic clinical trials in dengue.
Huyen TB, McBride A, Thein TL, Le KM, et al · · 2026 · PMID 42247469 · DOI 10.1371/journal.pntd.0014382

Verify or expand the search:

Other recruiting trials for Dengue Fever With Warning Signs

Currently open trials in the same condition.

NCT07409857 — International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR) · recruiting
NCT07007585 — Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection · recruiting
NCT05607472 — Factors Associated With Hospitalization for Dengue and Dengue Severity: Hospital-based Cohort Study on Reunion Island · NA · active not recruiting

Other Ilocos Training and Regional Medical Center trials

Trials by the same sponsor.

NCT06082674 — Novel Low Cost Bubble CPAP as an Alternative Respiratory Support in Low Resource Setting · Phase 2 · completed
NCT05033639 — Efficacy Of Oral Melatonin To Prevent Necrotizing Enterocolitis · Phase 1, PHASE2 · completed
NCT03911180 — Pertrochanteric Fracture Fixation In Elderly Adults Using Proximal Femoral Nail Anti-rotation (HERACLES) With a T-shaped · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05034809 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ilocos Training and Regional Medical Center
Last refreshed: 13 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05034809.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing